Related Experiment Videos
Health technology assessment. The pharmaceutical industry perspective
1Glaxo Wellcome Research and Development, United Kingdom.
Summary
Health technology assessment (HTA) guides pharmaceutical reimbursement decisions. Collaboration between industry and HTA agencies requires addressing challenges in clinical trials, economic evaluations, and transparency for fair value demonstration.
Area of Science:
- Health economics
- Pharmaceutical policy
- Clinical trial design
Background:
- Health technology assessment (HTA) is increasingly influential in pharmaceutical reimbursement and use recommendations.
- The pharmaceutical industry aims to partner with HTA agencies, but significant challenges exist.
Purpose of the Study:
- To outline challenges and propose solutions for effective collaboration between the pharmaceutical industry and HTA agencies.
- To emphasize the need for robust evidence generation and transparent decision-making processes.
Main Methods:
- The abstract discusses conceptual challenges and potential strategies for industry-HTA interaction.
- It highlights the importance of clinical trial design, economic evaluation harmonization, and real-world evidence collection.
Main Results:
- Clinical trials must incorporate economic and patient-reported outcomes alongside clinical endpoints.
- Demonstrating cost-effectiveness pre-launch may require conditional reimbursement and real-world data collection.
- HTA agencies must ensure unbiased, fair decision-making aligned with published guidelines.
Conclusions:
- Successful industry-HTA partnerships depend on transparent evidence submission and fair, rule-adherent assessments.
- Clear communication and mutual understanding of value are crucial for optimal pharmaceutical access and patient benefit.